Oculis Holding, a global biopharmaceutical company purposefully driven to save sight and improve eye care, has placed a follow-on public offering of 3.5m ordinary shares at a public offering price of USD 11.50 per ordinary share,
Tags :Natacha Tang
Oculis Holding, a global biopharmaceutical company, purposefully driven to save sight and improve eye care, listed its shares on Nasdaq after successfully closing the business combination between European Biotech Acquisition Corp. (“EBAC”). At closing, Oculis
As we have informed here, the AMR Action Fund, the world’s largest public-private partnership investing in biotech companies that are developing antimicrobials, has invested in BioVersys, a clinical-stage company based in Basel, Switzerland. The
